Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies

Maike Janssen,Albrecht Leo,Cornelia Wolf,Miriam Stenzinger,Marie Bartenschlager,Juliane Brandt,Sandra Sauer,Michael Schmitt,Peter Dreger,Richard F. Schlenk,Claudia M. Denkinger,Carsten Müller‐Tidow
DOI: https://doi.org/10.1002/ijc.34988
2024-05-11
International Journal of Cancer
Abstract:What's New? Hematologic cancer patients still have a high risk of prolonged infection and death from COVID‐19. So far, no definitive treatment has been established in this vulnerable patient group. Here, the authors report on a series of 21 immunocompromised patients with COVID‐19, most of them with hematologic malignancies, treated with plasma obtained from convalescent or vaccinated donors. The plasma retained activity against SARS‐CoV‐2 variants that had rendered monoclonal therapies ineffective, with plasma administration constituting a safe and feasible treatment. Virus clearance may allow to continue cancer therapy and decrease risk of infection to staff. Immunocompromised patients are at high risk to fail clearance of SARS‐CoV‐2. Prolonged COVID‐19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS‐CoV‐2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS‐CoV‐2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID‐19 infection. Here, we report on a series of 21 immunocompromised patients with COVID‐19—most of them hematologic malignancies—treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS‐CoV‐2‐antibody‐containing plasma could clear SARS‐CoV‐2 infection in 16 out of 21 immunocompromised patients even if COVID‐19‐specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS‐CoV‐2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS‐CoV‐2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10–24.25) to a median value of 29.57 (IQR = 27.55–34.63; p =
oncology
What problem does this paper attempt to address?